How to treat lobular cancer in the adjuvant setting?
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
23
8
2020
medline:
16
3
2021
entrez:
23
8
2020
Statut:
ppublish
Résumé
The aim of this review is to understand the clinical decision- making process for the management of patients with early invasive lobular breast cancer (ILC), thereby orienting clinicians across large areas of uncertainties and extrapolations. The analysis of the principal evidence on the management of ILC, assessing the role and benefit of systemic treatments in the curative setting, have shed the light on the opportunity to escalate and de-escalate systemic therapies for ILC patients, based on the risk of recurrence and the intrinsic value of the treatments. To refine the selection of the patients most likely to benefit from escalated systemic treatments, the role of genomic tools in ILC has been surveyed. Eventually, an overview of the ongoing clinical studies for early lobular tumors has been extracted. The review identifies large areas of uncertainties and unmet needs for the management of lobular cancer, urging the implementation of clinical studies appropriately designed, tailoring this subgroup of breast cancer patients. As a distinct biological and clinical entity, areas for improvement have been suggested, to support the formulation of controlled studies and better inform clinical decisions based on quality evidence.
Identifiants
pubmed: 32826487
doi: 10.1097/CCO.0000000000000674
pii: 00001622-202011000-00004
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
561-567Références
Lee JH, Park S, Park HS, Park BW. Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol 2010; 8:34.
IARC. Globocan 2018. Available at: https://gco.iarc.fr/. (Accessed 19 February 2020)
Burstein HS, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer. Ann Oncol 2019; 30:1541–1557.
Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol 2012; 23: (Suppl 8): viii10–viii14.
Jacobs C, Ibrahim MF, Clemons M, et al. Treatment choices for patients with invasive lobular breast cancer: a doctor survey. J Eval Clin Pract 2015; 21:740–748.
Orvieto E, Maiorano E, Bottiglieri L, et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 2008; 113:1511–1520.
Kourtidis A, Lu R, Pence LJS Anastasiadis##PZ. A central role for cadherin signaling in cancer. Exp Cell Res 2017; 358:78–85.
Schackmann RC, van Amersfoort M, Haarhuis JH, et al. Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest 2011; 121:3176–3188.
Zou D, Yoon HS, Perez D, et al. Epigenetic silencing in nonneoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. J Pathol 2009; 218:265–272.
Horne HN, Oh H, Sherman ME, et al. E-cadherin breast tumor expression, risk factors and survival: pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 2018; 8:6574.
Luveta J, Park RM, Heery DM, et al. Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy. Oncol Ther 2019; 8:1–11.
Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003; 29:361–367.
Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006; 17:1228–1233.
Delpech Y, Coutant C, Hsu L, et al. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 2013; 108:285–291.
Tamirisa N, Williamson HV, Thomas SM, et al. The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma. J Surg Oncol 2019; 120:132–141.
Truin W, Voogd AC, Vreugdenhil G, et al. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann Oncol 2012; 23:2859–2865.
Marmor S, Hui JYC, Huang JL, et al. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer 2017; 123:3015–3021.
de Nonneville A, Jauffret C, Gonçalves A, et al. Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast Cancer Res Treat 2019; 175:379–387.
Narbe U, Bendahl PO, Grabau D, et al. Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. Springerplus 2014; 3:70.
Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019; 380:2395–2405.
Singh K, He X, Kalife ET, et al. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results. Breast Cancer Res Treat 2018; 168:29–34.
Kizy S, Huang JL, Marmor S, et al. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Res Treat 2017; 165:757–763.
Felts JL, Zhu J, Han B, et al. An analysis of oncotype dx recurrence scores and clinicopathologic characteristics in invasive lobular breast cancer. Breast J 2017; 23:677–686.
Chen XH, Zhang WW, Wang J, et al. 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer. Biomark Med 2019; 13:83–93.
Herr D, Wischnewsky M, Joukhadar R, et al. Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective multicenter study. PLoS One 2019; 14:e0218434.
Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preopera- tive therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-operative ‘Arimidex’ Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106:2095–2103.
Rusz O, Vörös A, Varga Z, et al. One-year neoadjuvant endocrine therapy in breast cancer. Pathol Oncol Res 2015; 21:977–984.
van de Water W, Fontein DB, van Nes JG, et al. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer—a TEAM study analysis. Eur J Cancer 2013; 49:297–304.
Strasser-Weippl K, Sudan G, Ramjeesingh R, et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. Eur J Cancer 2018; 90:19–25.
Pagani O, Regan MM, Walley BA, et al. TEXT and SOFT Investigators, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107–118.
Francis PA, Pagani O, Fleming GF, et al. SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379:122–137.
Colleoni M, Luo W, Karlsson P, et al. SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018; 19:127–138.
Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016; 375:209–219.
Davies C, Pan H, Godwin J, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381:805–816.
Spring LM, Wander SA, Andre F, et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 2020; 395:817–827.
Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol 2020; 21:250–260.
Curigliano G, Loibl S. CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. Lancet Oncol 2020; 21:191–192.